A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies, Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology, Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 5/5/2017 |
| Start Date: | August 24, 2016 |
| End Date: | April 12, 2017 |
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Assess The Safety, Tolerability, And Pharmacokinetics With 2-weeks Of Dosing Of Pf-06427878 In Overweight-obese, Otherwise Healthy Adult Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary
purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2
weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.
purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2
weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.
Inclusion Criteria:
- Healthy male and/or female subjects of non childbearing potential.
- Body Mass Index (BMI) of >=25 kg/m2; and a total body weight >50 kg
- Subjects with liver fat >=6% and <=20%
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary,gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing).
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials